Associations between air pollution and pediatric eczema, rhinoconjunctivitis and asthma: A meta-analysis of European birth cohorts.


Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
03 2020
Historique:
received: 10 09 2019
revised: 20 12 2019
accepted: 06 01 2020
pubmed: 22 1 2020
medline: 12 9 2020
entrez: 22 1 2020
Statut: ppublish

Résumé

Uncertainly continues to exist regarding the role of air pollution on pediatric asthma and allergic conditions, especially as air pollution levels have started to decrease in recent decades. We examined associations of long-term air pollution levels at the home address with pediatric eczema, rhinoconjunctivitis and asthma prevalences in five birth cohorts (BIB, EDEN, GASPII, RHEA and INMA) from seven areas in five European countries. Current eczema, rhinoconjunctivitis and asthma were assessed in children aged four (N = 6527) and eight years (N = 2489). A multi-morbidity outcome (≥2 conditions versus none) was also defined. Individual outdoor levels of nitrogen dioxide (NO The overall prevalence of pediatric eczema, rhinoconjunctivitis and asthma at four years was 15.4%, 5.9% and 12.4%. We found no increase in the prevalence of these outcomes at four or eight years with increasing air pollution exposure. For example, the meta-analysis adjusted odds ratios (95% confidence intervals) for eczema, rhinoconjunctivitis and asthma at four years were 0.94 (0.81, 1.09), 0.90 (0.75, 1.09), and 0.91 (0.74, 1.11), respectively, per 10 μg/m In this large meta-analysis of five birth cohorts, we found no indication of adverse effects of long-term air pollution exposure on the prevalence of current pediatric eczema, rhinoconjunctivitis or asthma.

Sections du résumé

BACKGROUND
Uncertainly continues to exist regarding the role of air pollution on pediatric asthma and allergic conditions, especially as air pollution levels have started to decrease in recent decades.
OBJECTIVE
We examined associations of long-term air pollution levels at the home address with pediatric eczema, rhinoconjunctivitis and asthma prevalences in five birth cohorts (BIB, EDEN, GASPII, RHEA and INMA) from seven areas in five European countries.
METHODS
Current eczema, rhinoconjunctivitis and asthma were assessed in children aged four (N = 6527) and eight years (N = 2489). A multi-morbidity outcome (≥2 conditions versus none) was also defined. Individual outdoor levels of nitrogen dioxide (NO
RESULTS
The overall prevalence of pediatric eczema, rhinoconjunctivitis and asthma at four years was 15.4%, 5.9% and 12.4%. We found no increase in the prevalence of these outcomes at four or eight years with increasing air pollution exposure. For example, the meta-analysis adjusted odds ratios (95% confidence intervals) for eczema, rhinoconjunctivitis and asthma at four years were 0.94 (0.81, 1.09), 0.90 (0.75, 1.09), and 0.91 (0.74, 1.11), respectively, per 10 μg/m
DISCUSSION
In this large meta-analysis of five birth cohorts, we found no indication of adverse effects of long-term air pollution exposure on the prevalence of current pediatric eczema, rhinoconjunctivitis or asthma.

Identifiants

pubmed: 31962272
pii: S0160-4120(19)32848-X
doi: 10.1016/j.envint.2020.105474
pii:
doi:

Substances chimiques

Air Pollutants 0
Particulate Matter 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105474

Subventions

Organisme : Medical Research Council
ID : MR/N024397/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare they have no actual or potential competing financial interests.

Auteurs

Elaine Fuertes (E)

National Heart and Lung Institute, Imperial College London, London, United Kingdom; ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: e.fuertes@imperial.ac.uk.

Jordi Sunyer (J)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Ulrike Gehring (U)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands.

Daniela Porta (D)

Department of Epidemiology, Lazio Regional Health Service, ASL Roma 1, Rome, Italy.

Francesco Forastiere (F)

Department of Epidemiology, Lazio Regional Health Service, ASL Roma 1, Rome, Italy.

Giulia Cesaroni (G)

Department of Epidemiology, Lazio Regional Health Service, ASL Roma 1, Rome, Italy.

Martine Vrijheid (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

Mònica Guxens (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Department of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, Netherlands.

Isabella Annesi-Maesano (I)

Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Epidemiology of Allergic and Respiratory Diseases Department (EPAR), Saint-Antoine Medical School, Paris, France.

Rémy Slama (R)

Institute for Advanced Biosciences (IAB), INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France.

Dieter Maier (D)

Biomax Informatics AG, Munich, Germany.

Manolis Kogevinas (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Jean Bousquet (J)

Hopital Arnaud de Villeneuve University Hospital and Inserm, Montpellier, France.

Leda Chatzi (L)

Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.

Aitana Lertxundi (A)

CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Preventive Medicine and Public Health Department, University of Basque Country (UPV/EHU), Spain; Health Research Institute-BIODONOSTIA, Basque Country, Spain.

Mikel Basterrechea (M)

CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Health Research Institute-BIODONOSTIA, Basque Country, Spain; Public Health Division of Gipuzkoa, San Sebastián, Spain.

Ana Esplugues (A)

CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, 46020 València, Spain; Faculty of Nursing, University of Valencia, València, Spain.

Amparo Ferrero (A)

CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, 46020 València, Spain.

John Wright (J)

Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, United Kingdom.

Dan Mason (D)

Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, United Kingdom.

Rosie McEachan (R)

Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, United Kingdom.

Judith Garcia-Aymerich (J)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

Bénédicte Jacquemin (B)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; INSERM, U1168, VIMA: Aging and Chronic Diseases, Epidemiological and Public Health Approaches, Villejuif, France; Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, F-78180 Montigny le Bretonneux, France; Université Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH